Stephen Senn

Department of Statistics, University of Glasgow, United Kingdom

Stephen Senn

Academic positions:
- Professor of Pharmaceutical and Health Statistics at University College London (1995-2003)
- Professor of Statistics at Glasgow University (2003- present)

Any industry positions (last five years):
I consult regularly for the pharmaceutical industry and hold shares in Novartis as a consequence of having worked CIBA-Geigy.

Research interests:
Design and analysis of clinical trials, statistical inference, history of statistics, meta-analysis, ethics, decision analysis applied to drug development, drug safety.

Any other information:
His books, "Cross-over Trials in Clinical Research" and "Statistical Issues in Drug Development" are published by Wiley and his latest book, "Dicing with Death" by Cambridge University Press.

He is the recipient of
- George C Challis award for biostatistics of the University of Florida.
- PSI Award for most interesting speaker in 25 years of PSI, 2002
- Biopharmaceutical section of ASA award for best contributed paper 2002
- Awarded Honorary Membership of PSI, 2007

Current Editorial Board Memberships
- Applied Clinical Trials 2000-
- Pharmaceutical Statistics 2002-
- Methods of Information in Medicine 2006-
- Statistical Methods in Medical Research 1993-
- Wiley Statistics in Practice Series, Section Editor, Life and Biological Sciences, 2002-

Any competing interests declared are displayed with individual evaluations.

Section Head: Research Methodology > Statistical methodologies & health informatics (since 16 November 2005)

All recent recommendations

• 3.0
  Are flexible designs sound?
  Recommended by Stephen Senn
  
• 6.0
  Semiparametric analysis of case series data
  Recommended by Stephen Senn
  
• 3.0
  A likelihood approach to meta-analysis with random effects.
  Recommended by Stephen Senn
  
• 9.0
  Surrogate endpoints in clinical trials: definition and operational criteria.
  Recommended by Stephen Senn
  
• 9.0
  The performance of the two-stage analysis of two-treatment, two-period crossover trials.
  Recommended by Stephen Senn